EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

Gabriela Vega-Hernandez, Gordon MacGregor, Andrew Wilfin, Francis Adams, Ciarán Haugh, Carl A Baxter, Heike Wöhling, Sarah L Clarke, Susan C Charman, Siobhán B Carr

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2025.04.012 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Gabriela Vega-Hernandez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vertex Pharmaceuticals Incorporated, London, UK. Electronic address: gabriela_vega@vrtx.com. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vertex Pharmaceuticals Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The cystic fibrosis (CF) transmembrane conductance regulator modulator (CFTRm) elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has demonstrated efficacy and safety in clinical trials and emerging observational studies in people with CF. This study evaluated the real-world impact of ELX/TEZ/IVA in a large cohort of people with CF in the UK. METHODS: LONGITUDE is an observational, registry-based cohort study using data from the UK CF Registry to evaluate outcomes of ELX/TEZ/IVA in people aged ≥6 years who initiated ELX/TEZ/IVA from August 2019. Key outcomes included percent predicted forced expiratory volume in 1 s (ppFEV1), body mass index (BMI), pulmonary exacerbations (PEx), lung infections, transplants, deaths, and treatment discontinuation. We report results of people ≥12 years with data up to December 31, 2022. RESULTS: A total of 5187 people were included (mean follow-up 19.1 months). ppFEV1 improvements were observed at 2 years (10.2; 95 % CI: 9.6, 10.8; n = 1448). A clinically meaningful difference in the annual change of ppFEV1 between ELX/TEZ/IVA-treated people and historical CFTRm-naïve controls was observed, with those treated with ELX/TEZ/IVA having less of a decline in lung function over time by 1.1 percentage points (95 % CI: 0.9, 1.4). A 64.7 % reduction in the rate of PEx, increase in BMI by 1.7 kg/m2 (SD: 2.3), reduced lung infections, and low number of lung transplants and deaths were also observed. CONCLUSIONS: People with CF aged ≥12 years in the UK who initiated ELX/TEZ/IVA had sustained improvements in multiple CF-related health outcomes, consistent with results from clinical trials. These results support the positive impact of ELX/TEZ/IVA on the lives of people with CF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsBenzodioxolesQuinolonesIndolesPyrazolesPyrrolidinesHumansUnited KingdomMaleFemaleRegistriesDrug CombinationsAdolescentAdultChloride Channel AgonistsChildYoung AdultTreatment OutcomePyridines

Stichwörter der Autor:innen

Cystic fibrosisElexacaftorIvacaftorReal-worldRegistryTezacaftor

Substanzen

AminophenolsDrug CombinationsBenzodioxolesQuinolonesChloride Channel AgonistsIndolesPyrazolesPyridinesPyrrolidines

Autor:innen und Institutionen

  • Vertex Pharmaceuticals Incorporated, London, UK. Electronic address: gabriela_vega@vrtx.com.
  • Department of Respiratory Medicine, NHS Greater Glasgow and Clyde, Queen Elizabeth University Hospital, Glasgow, UK. Electronic address: gordon.macgregor@ggc.scot.nhs.uk.
  • Vertex Pharmaceuticals Incorporated, London, UK. Electronic address: Andrew_Wilfin@vrtx.com.
  • Cystic Fibrosis Trust, London, UK. Electronic address: FRANCIS.ADAMS@cysticfibrosis.org.uk.
  • Cystic Fibrosis Trust, London, UK. Electronic address: Ciaran.Haugh@cysticfibrosis.org.uk.
  • Vertex Pharmaceuticals Incorporated, London, UK. Electronic address: carl_baxter@vrtx.com.

Förderung

  • Vertex Pharmaceuticals Incorporated

Zitieren

APA

Vega-Hernandez, G., MacGregor, G., Wilfin, A., Adams, F., Haugh, C., Baxter, C. A., Wöhling, H., Clarke, S. L., Charman, S. C., & Carr, S. B. (2025). LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.04.012

Vancouver

Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, et al. LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.04.012

BibTeX
@article{VegaHernandez2025,
  author = {Vega-Hernandez, Gabriela and MacGregor, Gordon and Wilfin, Andrew and Adams, Francis and Haugh, Ciarán and Baxter, Carl A and Wöhling, Heike and Clarke, Sarah L and Charman, Susan C and Carr, Siobhán B},
  title = {LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2025.04.012}
}
Kostenlos starten →